United States Health News API

{
    "totalArticles": 129536,
    "articles": [
        {
            "id": "5e3a9aa9bfc834376b258ca2649b01de",
            "title": "GLP-1R-GIPR-PPARα/γ/δ quintuple agonism corrects obesity and diabetes in mice",
            "description": "There are increasing numbers of effective drugs to improve obesity-linked metabolic dysfunction; GLP-1R–GIPR co-agonism is effective in the management of obesity and type 2 diabetes1,2, and lanifibranor—a nuclear-acting small-molecule triple agonist of PPARα, PPARγ and PPARδ—is in clinical phase 3 trials for the treatment of metabolic dysfunction-associated steatohepatitis3. Here, seeking to further improve the metabolic efficacy of GLP-1R–GIPR co-agonism, we report the development of a unimolecular quintuple agonist that combines the body weight-reducing and blood glucose-lowering effects of GLP-1R–GIPR co-agonism with the insulin-sensitizing and anti-inflammatory effects of lanifibranor via its targeted delivery into GLP-1R- and GIPR-expressing cells. In vitro, GLP-1–GIP–lanifibranor is indistinguishable from GLP-1–GIP in relation to incretin receptor signalling and shows equal stimulation of insulin secretion in isolated mouse islets. In vivo, however, GLP-1–GIP–lanifibranor outperforms GLP-1R–GIPR co-agonism and semaglutide, further decreasing body weight, food intake and hyperglycaemia in obese and insulin-resistant mice through synergistic incretin and PPAR action. The metabolic action of GLP-1–GIP–lanifibranor is blunted in mice with genetic or pharmacological inhibition of GLP-1R, GIPR or PPARδ and is absent in DIO double incretin receptor-knockout mice, collectively suggesting that GLP-1–GIP–lanifibranor has substantial therapeutic value in the treatment of obesity and diabetes. GLP-1–GIP–lanifibranor, a single-molecule agonist of GLP-1R, GIPR, PPARα, PPARγ and PPARδ, shows promising therapeutic efficacy against obesity-linked metabolic dysfunction in vitro and in mouse models via synergistic incretin and PPAR activity.",
            "content": "In recent years, there has been a remarkable resurgence in drugs to treat obesity and its related co-morbidities. A standout example is tirzepatide, a co-agonist at the receptors for GLP-1 and GIP. In phase 3 clinical trials, tirzepatide improved liv... [22954 chars]",
            "url": "https://www.nature.com/articles/s41586-026-10427-5?error=cookies_not_supported&code=1b86951a-188f-4f18-8144-406584c3005c",
            "image": "https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41586-026-10427-5/MediaObjects/41586_2026_10427_Fig1_HTML.png",
            "publishedAt": "2026-04-29T22:15:05Z",
            "lang": "en",
            "source": {
                "id": "7abf0df285fbe93cdccffcc7c4088737",
                "name": "Nature",
                "url": "https://www.nature.com"
            }
        },
        {
            "id": "f9134b2c676e0bd90eda7474405be2d3",
            "title": "Spatial atlas of diabetic kidney disease reveals a B cell-rich subgroup",
            "description": "Diabetic kidney disease (DKD), the leading cause of kidney failure, is marked by clinical and molecular heterogeneity, making therapeutic development exceedingly difficult1. Here we used Xenium and CosMx single-cell spatial transcriptomics, integrated with single-nucleus RNA sequencing, to build a cross-platform kidney atlas that makes tissue architecture computable for prognosis, non-invasive detection and patient selection. Using this atlas, we defined reproducible tissue niches and injury-linked microenvironments and uncovered a profibrotic context that expands with disease and tracks with worse kidney function. Within this architecture, we identified a B cell-predominant, tertiary lymphoid structure-like immune microenvironment that defines a distinct DKD subset with accelerated progression to renal end-points. We developed tissue biomarkers and a matched plasma protein panel that capture this biology, stratify patients in a population biobank and improve risk prediction beyond clinical models—supporting their potential for biomarker-guided selection in future B cell-targeted DKD trials. A single-cell spatial atlas identifies a B cell-predominant microenvironment within the profibrotic tubular niche that marks a subset of patients with diabetic kidney disease with rapid progression.",
            "content": "Sample acquisition and ethics approval\nThe University of Pennsylvania institutional review board (IRB) approved the collection of human kidney tissue for this study. Left-over kidney samples were irreversibly de-identified, and no personal identifier... [36972 chars]",
            "url": "https://www.nature.com/articles/s41586-026-10363-4?error=cookies_not_supported&code=39b80fd3-733f-4cf9-b20b-80e114f95fdd",
            "image": "https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41586-026-10363-4/MediaObjects/41586_2026_10363_Fig1_HTML.png",
            "publishedAt": "2026-04-29T22:15:05Z",
            "lang": "en",
            "source": {
                "id": "7abf0df285fbe93cdccffcc7c4088737",
                "name": "Nature",
                "url": "https://www.nature.com"
            }
        },
        {
            "id": "fb29f5a9e3450381200c848b555d88e7",
            "title": "Somerville family in quarantine after exposure to measles on Boston-bound flight",
            "description": "A Somerville family is in quarantine after they were exposed to measles while on a flight to Logan Airport last week.",
            "content": "A Somerville family is in quarantine after they were exposed to measles while on a flight to Logan Airport last week. The Engel family was returning to Boston from Fort Lauderdale and was on the same flight as a passenger who tested positive for the ... [2571 chars]",
            "url": "https://www.wcvb.com/article/somerville-family-in-quarantine-after-exposure-to-measles/71167182",
            "image": "https://kubrick.htvapps.com/htv-prod/images/149047d9-e54e-46c8-8eb8-1dba5ebc762e.png?crop=0.998xw:1.00xh;0.00163xw,0&resize=1200:*",
            "publishedAt": "2026-04-29T21:03:00Z",
            "lang": "en",
            "source": {
                "id": "024664639a1a6f069fa542554d821136",
                "name": "WCVB",
                "url": "https://www.wcvb.com"
            }
        }
    ]
}